BioCryst Pharma (BCRX) Prices 37.93M Share Common Offering at $1.45/Sh

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced today the pricing of an underwritten public offering of 37,931,035 shares of its common stock, offered at a price to the public of $1.45 per share. The gross proceeds from this offering to BioCryst are expected to be $55 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst.

BioCryst has granted the underwriters a 30-day option to purchase up to an additional 5,689,655 shares of its common stock. The offering is expected to close on or about November 18, 2019, subject to customary closing conditions. BioCryst expects to use the net proceeds of this offering for general corporate purposes, which may include, but are not limited to, worldwide development, manufacturing, regulatory and commercial activities for the prophylactic BCX7353 program, primarily focusing on the U.S., EU and Japan; development of the BCX9930 program; development of the BCX9250 program; post-approval commitments for RAPIVAB®/ALPIVAB™; funding clinical development of pipeline assets; and capital expenditures and other general corporate expenses.

J.P. Morgan is acting as sole book-running manager for the offering. JMP Securities and H.C. Wainwright & Co. are acting as lead managers for the offering.

A shelf registration statement on Form S-3 relating to the shares of common stock described above has been previously filed with and declared effective by the U.S. Securities and Exchange Commission (“SEC”). This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

You May Also Be Interested In

• Q32 Bio prices $200 million stock offering at $18.25 per share
• LightPath Technologies gets $11M infrared camera order for C-UAS use
• Pasqal names former HPE computing executive as CCO for EMEA and APAC